The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings.
Axicabtagene ciloleucel, Kite
Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific antibodies epcoritamab and glofitamab, for relapsed/refractory diffuse large B-Cell lymphoma, showed improved progression-free survival (PFS). However, it was associated with higher rates of grade ≥3 cytokine release syndrome and neurological events.
Durvalumab and olaparib, AstraZeneca
A primary analysis of the DUO-E Phase III trial investigating durvalumab and olaparib in advanced or recurrent endometrial cancer showed an improvement in PFS compared to chemotherapy, reducing the risk-of disease progression or death by 45%.
Data from the Phase II THOR-2 Cohort 1 study demonstrated that erdafitinib improved PFS by 72% compared with intravesical chemotherapy in patients with papillary-only high-risk non-muscle-invasive bladder cancer with fibroblast growth factor receptor alterations who had recurrence after Bacillus Calmette-Guérin treatment and refused or are ineligible for radical cystectomy.
Data from the Phase III MARIPOSA study showed amivantamab plus lazertinib improved PFS by 30% compared to osimertinib in patients with first-line advanced EGFR-mutated non-small cell lung cancer (NSCLC).
The Phase III PAPILLON study demonstrated that in EGFR Exon 20 insertion-mutated advanced NSCLC, the median PFS was 11.4 months for amivantamab plus chemotherapy vs. 6.7 months for chemotherapy. The 18-month PFS rate was 31% vs. three percent.
The MAGNITUDE study showed PARP inhibitor niraparib plus abiraterone acetate and given with prednisone, improved OS and time to symptomatic progression (TSP) in patients with metastatic castration-resistant prostate cancer with BRCA1/2 mutations.
Datopotamab deruxtecan, Daiichi Sankyo and AstraZeneca
The companies shared results from multiple trials of their TROP2 directed DXd antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd).
BEGONIA Phase Ib/II trial, Dato-DXd plus durvalumab (Arm 7), previously untreated advanced or metastatic triple negative breast cancer: The combinationdemonstrated an objective response rate (ORR) of 79%, including six complete responses (CRs) and 43 partial responses (PRs). Median PFS was 13.8 months and median duration of response (DoR) was 15.5 months.
TROPION-Breast01 Phase III trial, inoperable or metastatic HR positive, HER2 low or negative breast cancer: Dato-DXd demonstrated a median PFS of 6.9 months compared to 4.9 months for chemotherapy, reduced the risk of progression or death by 37% and showed an ORR of 36.4% compared to 22.9%.
TROPION-Lung01 Phase III trial, NSCLC: Dato-DXd reduced the risk of disease progression or death by 25% in the overall population and by 37% in patients with non-squamous tumours. Median PFS was 4.4 months versus 3.7 with docetaxel and the ORR was 26.4% compared to 12.8%. In patients with non-squamous NSCLC, the ORR was 31.2%, including four CRs, versus 12.8%.
Enfortumab vedotin-ejfv, Astellas and Seagen
The Phase III EV-302 clinical trial showed that PADCEV (enfortumab vedotin-ejfv) plus pembrolizumab improved OS and PFS vs. chemotherapy by more than 50% in patients with previously untreated locally advanced or metastatic urothelial cancer. Patients treated with the combination had a median OS of 31.5 months compared to 16.1 for chemotherapy and a median PFS of 12.5 months compared to 6.3.
Tisotumab vedotin-tftv, Genmab and Seagen
Results from the Phase III innovaTV 301 trial showed treatment with TIVDAK demonstrated a 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. The ORR was 17.8% compared to 5.2%, while the disease control rate (DCR) was 75.9% compared to 58.2%.
LTX-315, Lytix Biopharma
Data were presented from ATLAS-IT-05, a Phase II trial of LTX-315 plus pembrolizumab in stage III-IV melanoma patients refractory to treatment with PD-1 / PD-L1 inhibitors. The combination demonstrated a DCR of 43%. Some patients showed significant tumour shrinkage in both injected and non-injected lesions.
In the Phase II KUNPENG trial, vebreltinib showed efficacy in patients with locally advanced or metastatic NSCLC harbouring Exon-14 skipping mutations, with an ORR of 75%. ORR and DCR were 100% in patients with brain metastases and ORR was 66.7% in patients with liver metastases. NSCLC patients with MetEx14 skipping mutation showed an ORR of 75%, median DOR of 15.9 months and a DCR of 96.2%.
Trastuzumab deruxtecan, AstraZeneca and Daiichi Sankyo
Enhertu achieved a median PFS of 6.9 months and median OS of 13.4 months in the DESTINY-PanTumor02 Phase II trial in patients with HER2-expressing solid tumours. ORR was 37.1% and DoR was 11.3 months.
Data from the TranStar102 study of Osemitamab (TST001) plus CAPOX chemotherapy in gastric and gastroesophageal cancer revealed a 55% RR, and a DoR and median PFS of more than 12 months for the expansion cohort. Of 49 patients (41 with CLDN18.2 positive tumours), 28 patients achieved PR, with 23 CR. The 12-month survival rate for cohort-C (64 patients) was 88.9%.
Diana Spencer, Senior Digital Content Editor, DDW